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Abstract
Background: Elucidating the activation pattern of molecular pathways across a given tumour type is a key
challenge necessary for understanding the heterogeneity in clinical response and for developing novel more
effective therapies. Gene expression signatures of molecular pathway activation derived from perturbation
experiments in model systems as well as structural models of molecular interactions ("model signatures”) constitute
an important resource for estimating corresponding activation levels in tumours. However, relatively few strategies
for estimating pathway activity from such model signatures exist and only few studies have used activation
patterns of pathways to refine molecular classifications of cancer.
Methods: Here we propose a novel network-based method for estimating pathway activation in tumours from
model signatures. We find that although the pathway networks inferred from cancer expression data are highly
consistent with the prior information contained in the model signatures, that they also exhibit a highly modular
structure and that estimation of pathway activity is dependent on this modular structure. We apply our
methodology to a panel of 438 estrogen receptor negative (ER-) and 785 estrogen receptor positive (ER+) breast
cancers to infer activation patterns of important cancer related molecular pathways.
Results: We show that in ER negative basal and HER2+ breast cancer, gene expression modules reflecting T-cell
helper-1 (Th1) and T-cell helper-2 (Th2) mediated immune responses play antagonistic roles as major risk factors for
distant metastasis. Using Boolean interaction Cox-regression models to identify non-linear pathway combinations
associated with clinical outcome, we show that simultaneous high activation of Th1 and low activation of a
TGF-beta pathway module defines a subtype of particularly good prognosis and that this classification provides a
better prognostic model than those based on the individual pathways. In ER+ breast cancer, we find that
simultaneous high MYC and RAS activity confers significantly worse prognosis than either high MYC or high RAS
activity alone. We further validate these novel prognostic classifications in independent sets of 173 ER- and 567 ER
+ breast cancers.
Conclusion: We have proposed a novel method for pathway activity estimation in tumours and have shown that
pathway modules antagonize or synergize to delineate novel prognostic subtypes. Specifically, our results suggest
that simultaneous modulation of T-helper differentiation and TGF-beta pathways may improve clinical outcome of
hormone insensitive breast cancers over treatments that target only one of these pathways.
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A key challenge to improve our understanding of the
heterogeneity in clinical outcome and response to ther-
apy is to map out the activation levels of cancer-relevant
pathways across clinical tumour specimens. To address
this goal, some studies have begun to characterise onco-
genic and cancer-signalling pathways in terms of “gene
expression signatures”, typically derived from perturba-
tion experiments that were performed in-vitro or in
model-systems, and in which specific signalling was
either enhanced or inhibited [1-4]. Most of the genes
that make up these perturbation signatures do not coin-
cide with those involved in the primary cascades follow-
ing the perturbation (as given for example by the local
protein-interaction network surrounding the perturba-
t i o n )[ 5 ] .I n s t e a d ,m o s to ft h eg e n e si nt h e s es i g n a t u r e s
reflect downstream transcriptional consequences of the
perturbation, which may nevertheless provide better
measures of upstream pathway activity [5]. Other studies
have focused on using literature curated databases of
molecular pathway interactions, thus taking the alterna-
tive view that consistency and trends in mRNA expres-
sion levels of interacting proteins may be used to infer
pathway activity [6-8]. In this work we refer to both the
perturbation signatures and molecular interaction mod-
els as “model signatures”. These same studies and others
have also begun to explore the clinical relevance of such
model signatures by inferring pathway activity across
human tumours and correlating the inferred patterns
with clinical variables [1,6,7,9-14]. As the studies in
[5,14] suggest, using molecular pathways may offer the
potential to delineate novel clinically relevant subtypes
within heterogeneous cancers.
Breast cancer patients with same histopathological fea-
tures demonstrate wide differences in clinical outcome.
For example, despite the aggressive high grade nature of
ER- disease, not all ER- patients have a poor clinical
outcome and a molecular subgroup of good prognosis
was recently identified in [15,16]. This subgroup was
characterised by overexpression of an immune-response
gene module and others have since reported similar
findings [17-23]. These results strongly implicate tumor
stromal cells, including T-cells and macrophages, as
molecular determinants of clinical outcome in breast
cancer [21]. However, results have also been mixed with
reports of inverse associations of immune response
genes with good prognosis, partly dependent on ER sta-
tus [18,24], and which have obscured the role of
immune cells in prognosis. More recently, it has been
shown that T-cell helper-2 (Th2) mediated immune
response pathways may promote tumor metastasis in
mammary carcinomas, in contrast to T-cell helper-1
(Th1) immune response pathways which are thought to
be tumor inhibitory [25,26]. In spite of this growing
interest in understanding the role of immune response
pathways in breast cancer, to date no study has investi-
gated if these pro and antimetastatic behaviours are
reflected in bulk tumour mRNA expression profiles and
how these relate to clinical outcome.
In view of this, we decided to take a bioinformatic
approach to dissect bulk tumour gene expression pro-
files in terms of model pathway signatures, in order to
shed further light on the prognostic role of immune
response and other important molecular pathways in
breast cancer. While statistical methods for inferring
pathway activation levels from corresponding model sig-
natures have been proposed [2,5,6,27-29], it has recently
become clear that model signatures exhibit a highly
complex modular structure that needs to be factored in
when estimating pathway activity [5]. For example, given
the genes that are coordinately up and downregulated
upon oncogene activation in a cell-line, not all of these
may demonstrate the same coherent up and down regu-
latory pattern in a tumour sample that has this onco-
gene activated. This may be because of other
perturbations (mutations) present in that tumour,
tumour cell heterogeneity, differences caused by the
tumour microenvironment, or because of inherent
cross-talk between molecular pathways. Motivated by
these difficulties, we propose a modular approach to
pathway estimation using ideas and methods from net-
work topology [30-32]. Unlike the clustering and factor
analysis approaches of [2,5,27,28], we allow the informa-
tion content of a model signature to be evaluated
against its expression pattern across a large panel of
tumour samples, thus allowing the consistency and rele-
vance of the model in the different cellular context to
be established before estimating module activity. The
evaluation of pathway consistency and activity scores
was also an approach used in [8]. Recent studies have
also shown the added value of using network based
approaches [6,33,34] and large expression compendia
[33-37] to derive gene modules associated with specific
cancer phenotypes. The work presented here differs
from most of these studies in that (i) our network
approach is totally unsupervised and (ii) that we tackle
the specific problem of pathway module activity estima-
tion without reference to a particular phenotype.
The main contributions of this manuscript are two-
fold. First, we propose a novel graph-theory framework
for obtaining pathway module activity estimates and
demonstrate the consistency of the method. Second, we
apply it to estimate activation levels of modules within a
number of important molecular pathways (HRAS, E2F3,
MYC, ERBB2, EGFR, AKT, IL12, IL2, IL4, IL13, IFNG,
TGFB) (Methods) [1,3,11,25,38,39] in ER+ and ER- breast
Teschendorff et al. BMC Cancer 2010, 10:604
http://www.biomedcentral.com/1471-2407/10/604
Page 2 of 20cancer and show that specific pathway modules synergize
to provide better prognostic stratifications of tumour
samples. Specifically, we demonstrate that ER- tumours
characterised by simultaneous high activation of a Th-1
differentiation module and low activation of a TGFB
pathway module have better clinical outcome than
tumours stratified by each pathway alone. Thus, estimat-
ing pathway module activity levels and considering mod-
els of combined pathway activation to delineate novel
prognostic subtypes may hold promise as a general tech-
nique for proposing novel and more effective combina-
tional therapies.
Methods
Data sets and molecular pathways
Central to our strategy is the availability of a large data
set in order to ascertain the most robust gene-gene cor-
relations. We constructed a large expression set by mer-
ging seven of the largest breast cancer data sets together
[2,24,40-44]. These data sets were chosen because of
their size, quality and available clinical outcome infor-
mation. The normalised data provided by the authors
was used and only probes that mapped to NCBI Entrez
ID identifiers selected. Probes mapping to the same
Entrez ID identifiers were averaged. We found 6265
genes in common between the seven studies. Samples in
each study were then divided up into estrogen receptor
negative and positive (ER-, ER+) tumours based on
available immunohistochemical information. This divi-
sion was necessary for the subsequent merging proce-
dure to work, because cohorts differed substantially in
terms of the relative proportions of ER- and ER+ tumors
and because ER- and ER+ tumors show widely different
gene expression profiles [40,41]. Next, for each set of ER
+ and ER- tumours within a study, we renormalised the
gene expression profile by a mean centering and scaling
the standard deviation to 1, yielding the z-score expres-
sion profile. For each common gene, z-scores were then
merged across all ER- cohorts, and similarly for all ER+
cohorts. This merging procedure was already validated
and shown to be a very fruitful approach [15,45]. For
the seven cohorts this yielded two large mRNA expres-
sion data sets of ER+ (785 samples) and ER- (438 sam-
ples) tumours over a common set of 6265 genes. We
validated the merging by performing a Singular Value
Decomposition (SVD) and demonstrating that none of
the top 20 singular values correlated significantly with
t h ec o h o r to fo r i g i n ,w h i l ec o r r e l a t i n gs i g n i f i c a n t l yw i t h
known intrinsic subtypes.
To assign intrinsic (SSP) subtypes within each study
we used spearman correlations between the intrinsic
centroids and the sample expression profiles followed by
a nearest centroid criterion [46]. This was done by map-
ping the genes in the centroids to the corresponding
averaged gene profiles on each indidividual platform (i.e
we considered the overlap with all genes in each study
and not just those overlapping the 6265 common
genes).
We selected a number of molecular pathways with
important roles in breast cancer: Ha-Ras1 proto-onco-
protein (HRAS), E2F transcription factor 3 (E2F3) and
c-myc proto-oncogene protein (MYC) [1], epidermal
growth factor receptor (EGFR) and c-erb B2/neu protein
(ERBB2) [3], AKT1 kinase (AKT) [11], interferon-
gamma (IFNG) [39], transforming growth factor beta-1
(TGFB) [38], interleukin-2,4,12,13 (IL-2,4,12,13) (http://
stke.sciencemag.org/, http://www.biocarta.com/, [25]). For
t h eH R A S ,E 2 F 3 ,M Y C ,E G F Ra n dE R B B 2p a t h w a y sw e
used as model signatures the perturbation signatures of
up and down regulation reported in the respective pub-
lications [1,3]. These signatures were derived from
human mammary epithelial cells and are reflective of
the perturbations in the respective oncogenes in inde-
pendent data [1,3]. For the pathways representing (AKT,
IFNG,TGFB) we used as model signatures the genes
reported to be upregulated upon activation of the path-
way [11,38,39] and which are part of the highly curated
Molecular Signatures Database (http://www.broadinsti-
tute.org/gsea/msigdb/). For the cytokine pathways we
used the highly curated pathway databases (http://stke.
sciencemag.org/, http://www.biocarta.com/)t oi d e n t i f y
genes which are normally upregulated in response to
these cytokines. The genes and their directionality of
regulation in each pathway are provided in Additional
file 1.
Rationale for a modular approach
Proposed methods for estimating pathway activity differ
mainly in terms of the amount of information contained
in the model signature that is subsequently used for
pathway activity estimation. In the simplest approach,
t h em o d e ls i g n a t u r ei st r e a t e da sag e n e - l i s ta n dp r o -
ceeds by clustering the genes across clinical tumour
samples to then infer activity scores over the separate
clusters [2]. The advantage of this approach is that it is
very plastic in that it recognises that a model signature
will break up into clusters or modules once the pattern
of expression of the constituent genes is investigated in
a different biological context. On the other hand, a
potential disadvantage is that it doesn’t use all the infor-
mation content in the model signature and thus does
not evaluate the consistency of the model signature in
the different context prior to pathway estimation. This
“clustering approach” contrasts with the Bayesian regres-
sion approach, where activity levels are estimated by
computing correlation-like scores between PCA compo-
nents inferred from a training set and the expression
p r o f i l eo fa n yg i v e ns a m p l e[ 2 7 , 2 8 ] .W h i l eac l e a r
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use of all the information content of the model signa-
ture, it is much less plastic as it implicitly assumes that
all of the genes and weights in the model signature are
relevant for estimating the activation of the correspond-
ing pathway in the different cellular context. Even if
model signatures are inferred by carefully avoiding over-
fitting in the training process, this would only avoid
overfitting if the “test” set samples were of the same
characteristics as the training samples, a condition
which is often not satisfied. To address this problem, a
modular approach like the ones used in [2,5] seems
necessary, as such methods recognise that not all genes
in the model signature are relevant for pathway
estimation.
In the case of prognostic signatures in ER+ breast can-
cer, as shown by Wirapati et al [12], signatures derived
in one cohort generally perform equally well in other
cohorts (where the evaluation is usually done using
direct correlations), suggesting that direct correlations
can be used in this context. However, breast cancer
samples derived from different cohorts represent biolo-
gically more similar entities, and therefore a signature
derived from one cohort may still be largely relevant in
another cohort, much more so than a cell-line derived
s i g n a t u r eo rap a t h w a ym o d e ld e r i v e df r o mt h e
literature.
Constructing expression relevance networks
Given a model signature we derived a relevance correla-
tion network across the two panels of ER+ and ER-
breast tumours as follows. First, we computed Pearson
correlations between every pair of genes in the model
signature also present in our ER+ and ER- expression
data sets. The Pearson correlation coefficients were then
transformed using Fisher’s transform
yij
ij
ij
=
+
−
1
2
1
1
log
c
c
(1)
where cij is the Pearson correlation coefficient between
genes i and j, and where yij is, under the null hypothesis,
normally distributed with mean zero and standard
deviation 13 / N s − with Ns the number of tumour
samples. Standard tests for significantly non-zero yij led
to a corresponding p-value matrix. To estimate the false
discovery rate (FDR) we needed to take into account the
fact that gene pair correlations do not represent inde-
pendent tests. Thus, we randomly permuted each gene
expression profile across tumour samples (a Monte
Carlo run) and selected a p-value threshold (0.0001)
that yielded a negligible average FDR (on average less
than 1 false positive as averaged over 1000 Monte Carlo
runs). Gene pairs with correlations that passed this
p-value threshold were assigned an edge in the resulting
relevance expression correlation network.
Evaluating significance and consistency of relevance
networks
The significance of the relevance networks was first
evaluated by comparing the average connectivity of the
observed networks with those of random subsets of
genes. Specifically, for each pathway in each of the ER+
and ER- subtypes we used 1000 random selections of
genes from the same merged data set and recomputed
the average connectivity of the resulting network. A
p-value of significance was then derived as the fraction
of randomisations that yielded an average connectivity
larger than the observed one.
The consistency of the derived pathway networks with
the prior model pathway information was evaluated as
f o l l o w s :g i v e na ne d g ei nt h ed e r i v e dn e t w o r kw e
assigned it a binary weight (1,-1) depending on whether
the correlation between the two genes is positive (1) or
negative (-1). This binary weight can then be compared
with the corresponding weight prediction made from
the model signature, namely a 1 if the two genes are
either both upregulated or both downregulated in
response to the oncogenic perturbation, or -1 if they are
regulated in opposite directions. Thus, an edge in the
network is consistent if the sign is the same as that of
the model prediction. A consistency score for the
observed network is obtained as the fraction of consis-
tent edges. To evaluate the significance of the consis-
tency score we used a randomisation approach.
Specifically, for each edge in the network the binary
weight was drawn from a binomial distribution with the
binomial probability estimated from the merged data
sets. We estimated the binomial probability of a positive
weight (1) as the fraction of positive pairwise correla-
tions among all significant pairwise correlations and was
found to be 0.6 and 0.56 for the ER- and ER+ data sets,
respectively. A total of 1000 randomisations were per-
formed to derive a null distribution for the consistency
score, and a p-value was computed as the fraction of
randomisations with a consistency score higher than the
observed one.
Module detection in networks
Given a network of n genes with adjacency matrix Aij
(Aij =1i fi and j are significantly correlated/anti-corre-
lated, otherwise Aij = 0) we were interested in identify-
ing modules/communities in this network, defined as a
partition of the network into subnetworks where the
internal edge density is relatively high compared to
the external one. This is analogous to finding clusters
of locally significantly correlated genes, given the
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the community detection problem based on the optimi-
zation of a quality function called modularity proposed
in [30], which allows the comparison of different parti-
tionings of the network. Given a network partitioned
into communities, being Ci the community to which
node i is assigned, the mathematical definition of modu-
larity is expressed in terms of the adjacency matrix as
Q
E
A
kk
E
CC ij
ij
j i
ij =−
⎛
⎝
⎜
⎞
⎠
⎟ ∑ ∑
1
22
(,) , (2)
where E is the number of edges in the network, and ki
= ∑j Aij refers to the degree of node i. The Kronecker
delta function δ(Ci, Cj) takes the values, 1 if nodes i and
j are in the same community, 0 otherwise.
The modularity of a given partition is then the probabil-
ity of having edges falling within groups in the network
minus the expected probability in an equivalent (null case)
network with the same number of nodes, and edges placed
at random preserving the nodes’ degree. The larger the
v a l u eo fm o d u l a r i t yt h eb e s tt h ep a r t i t i o n i n gi s ,b e c a u s e
more deviates from the null case. Several authors have
attacked the problem proposing different optimization
heuristics [30-32,47-50] since the number of different par-
titions grows at least exponentially with the number of
nodes n. Here, optimization of modularity was performed
using two different algorithms [32,51] and the best solu-
tion from 50 runs was used as the final partition.
Pathway activation metrics
We initially defined two main classes of pathway activa-
tion metrics on a given gene module. One metric is
based on single-gene based expression profiles for the
genes in the module, while the other uses the network
structure/topology of the module into account. The lat-
ter metric is motivated by the fact that the module over
which pathway activity is to be estimated (MPA) does
not generally constitute a clique, and therefore a score
of pathway activation should take the structure of the
module into account.
First, we define the single-gene based pathway activa-
tion metric. This metric is similar to the subnetwork
gene expression metric used in the context of protein-
interaction networks [6]. The metric for the module
(MPA) of size M is defined as,
 
s
M
z ii
iM P A
1
1
=
∈∑  (3)
where 
zi denotes the z-score normalised (mean zero
and unit variance) expression profile of gene i across the
tumours and si denotes the sign of pathway activation
(from the in-vitro model signature data), i.e si =1i f
upregulated upon activation, si =- 1i fd o w n r e g u l a t e d .
Thus, this metric, while it only takes those genes in the
MPA into account, it ignores the detailed topological
structure of the MPA.
To motivate the other class of pathway activation
metrics, we first rewrite the single-gene based metric in
terms of gene-pairs,
 
s
MM
fz z ij
ij PMPA
1
1
1
=
−
∈ ∑ ()
(, )
()
(4)
where fz z z z ij i i j j (, )
  
=+  is an additive function
of the gene expression profiles and where the summa-
tion is over all unique gene pairs (PMPA)i nt h eM P A
regardless of whether there is an edge between the two
genes or not. Thus, this now directly motivates a path-
way activation metric

s2 that does take the structure of
the MPA into account,
 
s
MM
Az z ij
ij P
ii jj
MPA
2
1
1
=
−
+
∈ ∑ ()
()
()
 (5)
Thus, this metric is only computed along the edges in
the MPA and gives more weight to those genes with
most connections. We therefore expect the measure

s2
to give a better representation of pathway activation
since

s1 also involves averaging over gene pairs that
need not be significantly correlated despite common
presence in the MPA. We have verified that such low-
correlated gene pairs exist in our MPAs, and results on
simulated data support the higher accuracy of

s2 (data
not shown).
Boolean Cox regression models
We considered non-linear interaction Cox proportional
hazards models. First, we binarised pathway activation
levels into high (1) and low activity (0) using the median
activity level across samples as the threshold. Let bi
denote the binary version of the pathway activity level
vector pi. We then considered Boolean regression mod-
els
ht b b h te
Bb b (| , ) ()
(,)
12 0
12 =
 (6)
where h(t) is the hazard function and B(b1, b2) denotes
a Boolean operator of the variables b1 and b2. For two
binary inputs, there are four distinct Boolean models
B b bB b bB b bB b b
cc c c
1 1 22 1 23 1 24 1 2 =∧ =∧ =∧ =∧ ,,, ,
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operations, respectively. These models were compared
to each other and to those based on single pathways to
determine if they provided better prognostic models. To
evaluate whether an interaction model added prognostic
value over the single pathway models, we compared the
log-likelihood of the combined model
htbb ht e c
bB b b i (| , ) ()
(,)
12 0
12 1 2 =
+  (7)
to that of the single pathways
htb ht e i si
bi (| ) () ,. =∀ = 0 12
 (8)
using the likelihood ratio test (LRT) (1 degree of free-
dom). Specifically, if lc = log L denotes the log-likelihood
of the combined model and li that of the single-pathway
model, we constructed the likelihood ratio test statistic
as LRTi =2*( lc - li), which under the null is c
2-distrib-
uted with 1 degree of freedom. Improved prognostic
pairwise models are obtained by those for which either
LRT1 or LRT2 is significantly larger than zero. Here we
restricted to pairwise models where pathways were indi-
vidually associated with prognosis and searched for pair-
wise combinations which further improved the
prognostic model.
Results
Estimating pathway activation using expression
network topology
The central hypothesis underlying our methodology is
that only a proportion of the genes in the model signa-
ture will show an expression pattern across the clinical
tumours that is consistent with their role as markers of
pathway activation. To help identify those genes that are
relevant from those that have inconsistent or irrelevant
expression patterns we make use of a large mRNA
expression data set of ER+ (785 samples) and ER- (438
samples) tumours over a common set of 6265 genes,
obtained by merging seven different cohorts together
("Set1”) [2,24,40-44]. These data sets were chosen
because they represent large high quality data sets with
the required clinical information (ER status and clinical
outcome). The seven microarray expression data sets
were merged over the common genes using a z-score
normalisation procedure that we have validated pre-
viously [15,45]. We verified, by performing a PCA analy-
sis on the merged data sets, that none of the top 20 PCs
were correlated with the cohort of origin but instead
where highly correlated with the intrinsic subtype, indi-
cating that samples clustered significantly according to
tumour subtype and not according to the original study
(Additional file 2).
Our strategy to estimate pathway activation for a given
model signature is llustrated in Figure 1 (see also Meth-
ods) and is carried out separately for ER+ and ER- dis-
ease. Briefly, the algorithm constructs a pruned
relevance correlation network of the genes in the model
signature across the expression tumour panel. Only
genes and correlations between genes that are consistent
with the prior information are allowed in the network.
This strategy therefore filters out genes and gene-pairs
with irrelevant or inconsistent expression patterns, while
also identifying modules of high-edge density, that is,
subnetworks of genes that show consistent and signifi-
cantly correlated (or anticorrelated) patterns across the
panel of tumours.
To further justify the need to filter out genes with
inconsistent expression profiles we show that not
doing so can lead to biologically inconsistent results.
Using all genes in two signatures of ERBB2 and EGFR
activation [1,3] to infer pathway activity in a large set
of breast tumour samples and using either Spearman
or Pearson correlations showed that predicted ERBB2
activity was not highest in the intrinsic HER2+ sub-
type, and similarly that EGFR activity was not highest
in the basal subtype (Additional file 3). These inconsis-
tencies are caused by a significant proportion of the
genes in the signatures not exhibiting the expected
correlations.
Significance and consistency of expression
correlation networks
We first observed that the relevance correlation net-
works for the model signatures contained on the order
of 10% to 25% of the maximum possible number of
edges (Table 1). We asked if this connectivity was
higher than that of a random subset of genes. In spite of
the much higher connectivity in ER+ disease, compari-
son to the null distribution showed that not all networks
in ER+ disease where significant (Table 1). In contrast,
all reasonably sized networks in ER- disease showed
higher connectivity than that expected by chance (Table
1). Next, we asked if the edges of the networks, repre-
senting significant correlations or anti-correlations, were
consistent with the prior information of the model sig-
nature (Table 1, Methods). Reassuringly, almost all net-
works showed statistically significant consistency (P <
0.001) with the model data indicating the potential of
using such model signatures to estimate pathway activity
across clinical tumour specimens (Table 1). Consistency
scores however varied considerably depending on the
pathway considered (50% - 100%). In view of the fact
that a proportion of edges showed inconsistent patterns
with the model data, these were removed to yield
“pruned” correlation networks.
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Next, we applied a spectral decomposition algorithm
[50,51] to infer subnetworks of relatively high edge den-
sity, which we called modules (Methods). We confirmed
the modularity of the networks and the presence of rela-
tively small outlier modules in several pathways (Addi-
tional file 4). Given the smaller size of the immune
response and interferon pathway gene lists, these path-
ways were not broken up into modules. For the larger
model signatures containing several large modules, we
explored if pathway activation would be dependent on
the specific module. Thus, we estimated the activity for
the largest modules in each pathway and asked if the
activities of the individual modules were highly corre-
lated. Interestingly, this showed that many modules
within a pathway were not highly correlated and that in
some cases correlations were even negative (Additional
file 5). This result agrees with findings reported in [5].
Figure 1 Measuring pathway module activation. Flowchart figure showing overall strategy used for inferring pathway module activity in
clinical tumor samples from a model (perturbation) signature. A) A gene mRNA signature that represents a perturbed cancer cell phenotype (i.e
oncogene overexpression) is combined with mRNA expression data of a large panel of clinical tumor specimens to derive an “expression
relevance network” where nodes represent genes from the signature and an edge between two nodes indicates a statistically significant Pearson
correlation between the two corresponding genes as measured over the clinical tumor panel. Having constructed the relevance network, the
network is first pruned so that network edges that are inconsistent with prior information are removed. Signs on edges between labelled genes
indicate the sign of the significant correlation between the two genes, which must be consistent with their directionality as given by the model
signature. Modules defined as subnetworks with higher than average edge density are then inferred using a spectral decomposition algorithm
(see Methods). B) For a given relatively large module, the module of pathway activation (MPA), pathway activity is then computed using a
metric defined over the topology of the module. In the formula, PAs stands for the estimated pathway module activity in sample s, M is the
number of genes in the module, si is a binary weight (1,-1) indicating the directionality of gene expression of gene i (1 = upregulated, -1 =
downregulated), zis is the z-score normalised gene expression value in sample s and Aij is the adjacency matrix of the module. Effectively, this
metric gives more weight to gene interactions that are supported by the data. Color and sign of nodes reflect the directionality of expression in
the in-vitro signature (Red = upregulated &s = 1, Green = downregulated &s = -1). Pathway activity levels can then be shown as heatmaps
(blue = high activity, yellow = low activity).
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pathway, we therefore selected the module containing
the gene undergoing the perturbation. This criterion
could be used to select modules for the MYC (MYC),
RAS (HRAS), ERBB2 (ERBB2), AKT (AKT1)a n dE G F R
(EGFR) pathways. For the E2F3 and TGFB pathways we
used CCNE1 and COL3A1, which are well known down-
stream targets of E2F3 and TGFB, respectively [1,38].
Given the smaller size of the immune response and
interferon pathways, pathway activity estimation for
these was performed on the whole network (i.e no mod-
ule selection). Gene members, their interactions in the
selected modules plus directionality of regulation are
listed in Additional file 6. Heatmaps of all genes in the
selected modules across ER+ and ER- breast cancer
confirmed their significant within-module correlations
and anticorrelations (Additional file 7).
Patterns of pathway activation correlate with intrinsic
subtypes
The estimation of activity levels for the selected mod-
ules across clinical tumours yielded a pathway activity
level matrix. Clustering was performed using a varia-
tional Bayesian mixture model [52] over the 8 largest
molecular pathway modules to see if samples segre-
gated significantly according to intrinsic subtype [46]
(Figure 2A). We observed that inferred clusters
mapped to intrinsic subtypes, as well as providing evi-
dence for further heterogeneity within subtypes, con-
firming similar results reported in [14]. In line with
the fact that intrinsic subtypes in ER+ breast cancer
show differences in distant metastasis free survival
(DMFS), inferred clusters also correlated significantly
with outcome (Figure 2B). Importantly, we observed a
significant survival difference in ER- breast cancer with
those samples having overactive TGFB exhibiting worst
survival (Figure 2B).
From the heatmap and boxplots of pathway activity
across intrinsic subtypes (Figures 3A-H &4A-H, Addi-
tional file 8) we could draw the following observations,
all of which are consistent with prior knowledge:
￿ Activity of the ERRB2 pathway was highest in the
HER2+ subtype (P <1 0
-10).
￿ Activity of the EGFR signalling pathway was high-
est in the basal and normal subtypes of ER- breast
cancer in line with the higher levels of EGFR in
these tumours [2] (P <1 0
-8).
￿ Higher activation of MYC and E2F3 pathways in
luminal-B tumours compared with luminal-A, an obser-
vation consistent with many previous results associating
amplification of the 8q24 locus and overexpression of
cell-cycle and proliferation genes with the more aggre-
sive luminal-B phenotype [43,53-55] (P <1 0
-10).
We also observed other patterns of interest that lend
further support for similar results reported elsewhere:
￿ Higher AKT activity in the ER-/HER2+ subtype as
compared to ER- basal breast cancer [2,11](P <1 0
-10).
￿ Higher HRAS activity in luminal-B tumours rela-
tive to luminal-A [2] (P <1 0
-10).
￿ Lower HRAS activity in basal tumours, with a cor-
responding lower expression of HRAS in basals as
compared to ER-/HER2+ [2](P <1 0
-10).
Thus, these patterns yield insight into which molecu-
lar pathway modules are differentially activated between
intrinsic subtypes.
Table 1 Molecular pathways and properties of their
expression networks
ER-
Pathway nG nE fE Pval(signif) fconsE Pval(consist)
MYC 76 472 0.17 < 0.001 0.88 < 0.001
E2F3 104 793 0.15 < 0.001 0.58 < 0.001
RAS 135 1387 0.15 < 0.001 0.63 < 0.001
ERBB2 228 4223 0.16 < 0.001 0.84 < 0.001
EGFR 180 2395 0.15 < 0.001 0.66 < 0.001
AKT 41 346 0.42 < 0.001 1.00 < 0.001
IL12 17 38 0.28 < 0.001 0.95 < 0.001
IL4 11 9 0.16 0.11 1.00 < 0.001
IL2 19 22 0.13 0.19 0.73 0.009
IL13 7 6 0.29 0.01 1.00 < 0.001
INFG 40 222 0.28 < 0.001 0.90 < 0.001
TGFB 62 479 0.25 < 0.001 0.92 < 0.001
ER+
Pathway nG nE fE Pval(signif) fconsE Pval(consist)
MYC 76 749 0.26 0.24 0.79 < 0.001
E2F3 104 1285 0.24 0.58 0.57 < 0.001
RAS 135 2231 0.25 0.48 0.57 < 0.001
ERBB2 228 7336 0.28 0.01 0.74 < 0.001
EGFR 180 4286 0.27 0.13 0.66 < 0.001
AKT 41 676 0.82 < 0.001 1.00 < 0.001
IL12 17 32 0.23 0.53 0.97 < 0.001
IL4 11 10 0.18 0.72 0.70 0.06
IL2 19 40 0.23 0.51 0.60 0.08
IL13 7 6 0.29 0.28 0.50 0.35
INFG 40 284 0.36 0.003 0.83 < 0.001
TGFB 62 713 0.38 < 0.001 0.86 < 0.001
Properties of the inferred relevance expression correlation networks in ER-
and ER+ breast cancer. For each molecular pathway we give the number of
pathway genes present in the expression matrix (nG), the number and
fraction of edges (i.e significant pairwise correlations between genes) (nE &
fE), the significance of the average connectivity of the network (Pval(signif)),
the fraction of edges that are consistent with the prior in-vitro information
(fconsE), the corresponding p-value of significance (Pval(consist)). P-values
were estimated using 1000 permutations.
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Page 8 of 20Figure 2 Clustering analysis over pathway modules. A) Heatmaps of pathway activation (blue = high relative activation, yellow = low relative
activation) over the merged ER- and ER+ cohorts [2,24,40-44]. Color bars indicate the intrinsic subtype (Pink = HER2+, green = normal, dark-red
= basal, skyblue = luminal A, blue = luminal B) and the cluster inferred using a variational Bayesian method [52]. B) Kaplan Meier plots for distant
metastasis free survival (DMFS) for the predicted clusters in ER- and ER+ breast cancer, respectively.
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Page 9 of 20Pathway activation patterns are preserved in
independent cohorts
In order to check the robustness of the pathway activity
patterns in relation to the intrinsic subtype classification,
we asked whether the identified modules showed the
same pattern of variation in external independent
cohorts. To this end, we collected the normalised
expression data for four additional breast cancer cohorts
[18,56,57] including the expression oncology (expO)
data set (http://expo.intgen.org/geo/). This validation set
(Set2) thus consisted of 657 ER+ and 173 ER- tumour
samples. Pathway activity scores for the modules derived
from the large training set were then evaluated in each
of these test cohorts using the same metric as used in
the training set and subsequently merged together.
Thus, only edges significant in the training set were
used to evaluate pathway activity in the validation sets.
We found that the patterns of differential activation for
each of the modules was highly consistent between
training and validation sets, indicating that (i) our meth-
odology for evaluating activity scores is robust, and (ii)
that the identified modules may have biological signifi-
cance (Figures 3I-P &4I-P). In fact, we asked how many
of the predicted (i.e significant) pathway activation dif-
ferences between major SSP subtypes in each ER+/ER-
class were also significantly different in Set2 (Additional
file 8). This showed that for ER+ and ER- disease, 92%
and 81% of all pairwise significant differences in the
training set were also significantly different in the vali-
dation set, with 98% and 100% of these showing the
same directional change. In addition, we also observed
consistency in the scale and range of activation scores
for a given pathway across training and validation sets
(Figures 3 &4).
Figure 3 Pathway module activation scores across intrinsic subtypes in ER+ breast cancer. A-H) For the selected module in each
pathway, we show boxplots of predicted pathway module activation scores across the major intrinsic subtypes within ER+ breast cancer as
estimated in Set1. I-P) Corresponding boxplots as estimated in Set2. Number of samples in each subtype shown above corresponding boxplot.
(Color Code: green = normal, skyblue = lumA, blue = lumB, pink = HER2+).
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Page 10 of 20Correlations between pathway modules reveals patterns
of signal transduction
Next, we investigated the correlation pattern between
molecular pathway modules (Figure 5A). In both ER-and
ER+ breast cancer we observed a strong correlation
between the ERBB2, RAS and AKT pathways (Pearson cor-
relation between RAS and AKT was 0.61 in ER+ and 0.59
in ER-), consistent with AKT-signalling a direct down-
stream target of RAS and ERBB2 [3,58,59]. Interestingly, in
ER+ breast cancer these pathways were also correlated
with MYC and E2F3. MYC and E2F3 pathways showed
mutual strong correlations (Pearson correlations: 0.59 in
ER+, 0.24 in ER-), consistent with E2F being a known tran-
scriptional downstream target of MYC [60,61]. Another
cluster was made up of immune response pathways.
Specifically, IL12, IL2 and IFNG, all involved in Th1
mediated immune response [25,26], showed strong
correlations in both ER+ and ER- breast cancer, while
IL13 (involved in a Th2 immune response) was generally
anti-correlated to these pathways.
To evaluate the robustness of these patterns we com-
puted the pairwise module correlations in the external
cohort set (Set2) and compared these values to the ones
in Set1. We observed strong agreement between the two
data sets (Figure 5B).
Pathway interactions define novel prognostic subclasses
Next, we asked if individual module activation levels
were correlated with distant metastasis free survival
(DMFS). Pathway module activation levels were dichoto-
mised into high and low activity in order to help inter-
pretability of pathway interaction terms and ease
comparison between multiple and single pathway mod-
els. First, using univariate Cox-proportional hazards
Figure 4 Pathway module activation scores across intrinsic subtypes in ER- breast cancer. A-H) For the selected module in each pathway,
we show boxplots of predicted pathway module activation scores across the major intrinsic subtypes within ER- breast cancer as estimated in
Set1. I-P) Corresponding boxplots as estimated in Set2. Number of samples in each subtype shown above corresponding boxplot. (Color Code:
green = normal, pink = HER2+, red = basal).
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Page 11 of 20regression models we found that E2F3, MYC and RAS
overactivation were associated with poor prognosis in
ER+ breast cancer (P < 0.01, Table 2). In a multivariate
model including all three, only E2F3, which defines a
proliferation module, remained prognostic. Interestingly,
while IL12 and IL2 activation showed a trend towards
favourable outcome, IL13 wasm a r g i n a l l ya s s o c i a t e d
with poor prognosis (Table 2). In ER- breast cancer,
IL12, IL2 and IFNG were significantly associated with
good prognosis, while TGFB and EGFR pathway activa-
tion were associated with poor clinical outcome (Table
2). Similar to the pattern in ER+ disease, IL13 was mar-
ginally associated with poor clinical outcome in ER-
breast cancer (Table 2). We observed similar patterns of
association in Set2, and in particular while IL12, IL2
and IFNG were associated with good prognosis in ER-
breast cancer, IL13 correlated with poor outcome (Addi-
tional file 9).
Figure 5 Correlation patterns of molecular pathway modules. A) Pearson correlation heatmaps between molecular pathway modules in the
ER- and ER+ breast cancer (Set1), respectively (Red = high positive correlation, White = zero or insignificant correlation, Green = high negative
correlation). B) Validation of pairwise pathway module Pearson correlations in external set (Set2). Left panel (ER-), right panel (ER+). Overall
Pearson correlation (PC) between training (Set1) and validation set (Set2) is given.
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Page 12 of 20The association of high expression of genes in the Th1
immune response pathways (IL12, IL2, IFNG) with good
prognosis is consistent with their putative tumor-inhibi-
tory role [25,26]. Given that this tumor-inhibitory role
could be compromised by antagonistic Th2 (IL13, IL4)
and TGFB pathways [25,26], we hypothesized that
tumours exhibiting simultaneous high Th1 and low TGFB
activity may exhibit a better prognosis than tumors strati-
fied by each pathway alone. To test this and to look for
other pathway module interactions which may provide
better prognostic stratifications, we applied logic (Boolean)
Cox regression models to all pairwise combinations of
pathways which were individually prognostic (Methods).
For each pathway pair we identified the most predictive
non-linear pathway combination and determined if it pro-
vided a better prognostic model (Methods).
In ER- breast cancer, we observed that IL12 (or IFNG)
synergized with TGFB to provide a better prognostic
model than either pathway considered separately (Figure
6A). Specifically, simultaneous high IL12 (or IFNG) and
low TGFB activity defined a good prognosis subtype
relative to all other samples (HR = 0.41 (0.26-0.64) P <
10
-4)( F i g u r e7 A ) .M o r e o v e r ,t h i sr e s u l th e l dt r u ei n
both basal and HER2+ subtypes (Additional file 10).
Using likelihood ratio tests we verified that the non-lin-
ear interaction between IL12 (IFNG) and TGFB added
prognostic value over models based on only TGFB or
IL12 (Figure 6B). Conversely, the single pathway models
did not improve the prognostic model provided by the
non-linear interaction term (Figure 6C). We also
observed that stratifying ER- samples according to high
EGFR low IL12/IFNG activity provided a better prog-
nostic model than stratifications based on the indivi-
duals pathways (Figure 6A), and Specifically that this
non-linear interaction added prognostic value over the
model using IL12/IFNG alone (Figure 6B). Consistent
with this, simultaneous high EGFR low IL12/IFNG
activity defined a subtype of poor prognosis (HR = 2.43
(1.71-3.44) P <1 0
-6, Additional file 11).
In ER+ breast cancer we observed that high MYC syner-
gized with high RAS activation to provide a better prog-
nostic stratification than either high MYC or high RAS
alone (Figure 6A), and that this non-linear MYC-RAS
interaction added prognostic value over the single-pathway
models (Figure 6B). In contrast, adding single MYC or
RAS module activities to the MYC-RAS interaction model
did not improve the prognostic model (Figure 6C). We
verified using Kaplan Meier curves that simultaneous high
MYC and high RAS defined a subtype of poor clinical out-
come (Figure 7B). However, neither of these pathways nor
their interaction provided a better prognostic model than
that provided by the E2F3 pathway (Figure 6).
In order to validate these findings, we dichotomised the
pathway activation levels of IL12, TGFB, EGFR, RAS and
MYC pathways in the ER- and ER+ samples of the test
set (Set2), and first evaluated if the four subgroups, strati-
fied according to high/low activity of the two pathways,
showed differences in clinical outcome. Once again we
observed that combined high IL12 low TGFB defined a
good prognosis subtype in ER- breast cancer (HR = 0.11
(0.01-0.78) P = 0.007, Figure 7C) and that the stratifica-
tion based on the combined activity levels provided a bet-
ter stratification than that based on the individual
pathways (Additional file 12). Similarly, simultaneous
high RAS high MYC activity defined a poor prognosis
subtype in ER+ disease (HR = 2.11 (1.39-3.21) P <0 . 0 0 1 ,
Figure 7D) and provided a better stratification than the
model based on the individual pathways (Additional file
Table 2 Correlations of pathway modules with outcome in breast cancer
ER+ (n = 785) ER- (n = 438)
HR 95%CI Pval HR 95%CI Pval
MYC 1.5 1.16-1.95 0.002 0.82 0.58-1.16 0.27
E2F3 2.23 1.7-2.92 < 10
-8 0.71 0.5-1 0.05
RAS 1.38 1.06-1.79 0.02 1.13 0.8-1.59 0.5
ERBB2 1.06 0.82-1.38 0.64 1.29 0.91-1.82 0.15
EGFR 0.93 0.72-1.21 0.59 1.82 1.28-2.59 < 0.001
AKT 1.29 0.99-1.67 0.06 1.49 1.05-2.11 0.02
IL12 0.88 0.68-1.15 0.35 0.52 0.36-0.74 < 0.001
IL4 0.96 0.74-1.25 0.77 0.93 0.66-1.31 0.69
IL2 0.88 0.68-1.14 0.32 0.7 0.5-1 0.05
IL13 1.28 0.98-1.66 0.07 1.29 0.91-1.82 0.15
IFNG 1.09 0.84-1.42 0.5 0.58 0.41-0.82 0.002
TGFB 0.93 0.71-1.2 0.57 1.65 1.16-2.34 0.004
For ER+ and ER- breast cancers in Set1 and for each pathway, we give the hazard ratio, 95%CI and the log-rank test P-value from a stratified Cox-proportional
hazards regression model with cohorts as strata and with distant metastasis free survival (DMFS) as clinical endpoint. Pathway activation levels were divided into
high/low activity levels according to values larger/lower than the median. Number of samples is given by n.
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Page 13 of 20Figure 6 Improved prognostic models through non-linear interactions of pathway modules. A) For pathways that correlated with DMFS in
ER+ and ER- breast cancer (Table 2), we consider corresponding Boolean interaction Cox regression models describing the pairwise interaction of
any two pathways (the best model out of a total of 4, i.e up-up, up-down, down-up, down-down, is shown). y-axis labels the pathway interaction
pair and best boolean model, x-axis denotes the log-likelihood of the corresponding model. (Black = log-likelihood of model for first pathway in
pair, Grey = log-likelihood of model for second pathway in pair, Red = log-likelihood of the best Boolean interaction model, pink dashed line
highlights those Boolean models with improved log-likelihoods). B) Heatmaps of likelihood ratio test (LRT) p-values comparing nested prognostic
models. Specifically, LRT p-value for pathway py on y-axis and pathway px on x-axis is obtained by comparing Cox-regression models with the
single pathway px plus non-linear Boolean interaction B(px, py) as predictors against the model with only px as predictor. C) As B), but LRT p-value
for pathway py on y-axis and pathway px on x-axis is obtained by comparing Cox-regression models with the single pathway px plus non-linear
Boolean interaction B(px, py) as predictors against the model with only B(px, py) as predictor. Color codes: red (P < 0.01), pink (P < 0.05), white (P >
0.05). All Cox regression were stratified regression using the cohorts as strata to account for variations in the hazard rate between cohorts.
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Page 14 of 2012). Although only marginally significant, high EGFR low
IL12 activity displayed the same trend as in Set1, confer-
ring poor prognosis in ER- breast cancer (HR = 1.86
(0.83-4.17) P = 0.12, Additional file 11).
Discussion
We have shown that model signatures exhibit bulk
tumour gene expression patterns that are generally
highly consistent with the information contained in the
model (Table 1). In agreement with [5] we also found
that model signatures break up into distinct modules,
in some cases exhibiting widely different activity pat-
terns, supporting the view that pathway activity estima-
tion ought to be performed after a module detection
step. The modularity of the model signatures may
reflect differences in cellular context (e.g comparing
in-vitro culture to in-vivo conditions), the plethora of
genomic abnormalities underlying any given tumour,
and also inherent complex cross-talk between molecu-
lar pathways. To simplify the analysis, for those model
signatures exhibiting high modularity we selected the
module containing the gene undergoing the perturba-
tion. Thus, the activation levels we report are for a
specific module within the pathway and therefore may
not necessarily reflect the overall pathway activation
level, or provide the best estimate of pathway activa-
tion. The latter task is a complex endeavour that we
hope to address in the near future using the imminent
large scale multidimensional breast cancer array data
sets.
However, by relating the predicted module activity
patterns to the existing intrinsic subtype classification
Figure 7 Novel prognostic subtypes in ER- and ER+ breast cancer. A) & B) Kaplan Meier DMFS curves for dichotomised pathway activity
levels, for IL12 and TGFB, in ER- breast cancer (Set1). C) Corresponding Kaplan Meier curve for the four subtypes stratified according to up/down
activity of the two pathways. Hazard ratio refers to the IL12up-TGFBdn subtype relative to the rest. D) Independent validation in the test cohort
(Set2). E) & F) Kaplan Meier DMFS curves for dichotomised pathway activity levels, for MYC and RAS, in ER+ breast cancer (Set1). G)
Corresponding Kaplan Meier curve for the four subtypes stratified according to up/down activity of the two pathways. Hazard ratio refers to the
MYCup-RASup subtype relative to the rest. H) Independent validation in the test cohort (Set2).
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Page 15 of 20[46], we showed that the activation patterns of our
inferred modules were highly preserved in independent
test sets (Figures 3 & 4), which not only demonstrates
the robustness of our proposed method, but also shows
that the pathway modules we have identified are of bio-
logical significance and that they may be used to provide
an alternative clinically more relevant molecular classifi-
cation of breast cancer.
Using our approach we also rediscovered known rela-
tions between molecular pathways. For example, we
observed strong correlations between MYC and E2F3
pathways, consistent with E2F3 a direct downstream tar-
get of MYC (MYC® E2F3), as well as strong correla-
tions between ERBB2, RAS and AKT, consistent with
the known signalling cascade ERBB2®RAS®AKT
[58-61]. We verified that these correlations could not be
explained by an overlap in the genes, as the modules
exhibited minimal overlap.
Interestingly, we also observed correlations between
pathways (IL12, IFNG, IL2) involved in Th1 mediated
immune response, as well as correlations between path-
ways (IL13, TGFB) that act via Th2 immune responses
to putatively suppress the tumor inhibitory role of Th1
pathways (Figure 5) [25,26]. Moreover, Th1 and Th2
(IL13) pathways were generally anti-correlated and while
Th1 activation was clearly associated with good prog-
nosis, Th2 (IL13) and TGFB activation were associated
with poor prognosis (Table 2 & Additional file 9). Thus,
it is tentative to speculate that the balance of Th1 and
Th2 differentiation pathways in the tumour microenvir-
onment is a determinant of distant metastasis in ER-
breast cancer (Figure 8). Supporting this model, we
observed that ER- tumours with simultaneous low
TGFB and high IL12 activity had significantly better
outcome and that stratification based on the combina-
tion of these two pathways provided a better prognostic
classification than those based on single pathways (Fig-
ures 6 & 7). Importantly, these results were validated in
an independent cohort and in both the ER-/basal and
ER-/HER2+ subtypes (Additional file 10). We also veri-
fied that Th1 (IL12, IFNG) and Th2 (TGFB) modules
retained the same prognostic power in multivariate
models including E2F3, itself strongly prognostic in ER+
breast cancer but only marginally so in ER negatives.
Since E2F3 is a proliferation module, this demonstrates
once again that in ER- breast cancer, immune response
pathways play a much more prominent prognostic role
than proliferation.
Figure 8 Proposed model of how immune response pathways affect clinical outcome in ER- breast cancer. Figure adapted from [26].
Hypothetical model in which the balance of cytokines in the breast tumour microenvironment determines the relative strength of Th1 and Th2
differentiation. Stronger activation of a Th1 immune response leads to increased production of IL2 and IFNG which mediate formation of M1
macrophages and cytotoxic killer cells, which is tumour inhibitory [26]. Correspondingly we observe that genes that are upregulated in these
pathways are associated with good prognosis (DMFS) in ER- breast cancer (significant associations shown in green). Conversely, stronger
activation of a Th2 immune response leads to production of IL13 and TGFB cytokines through an M2 macrophage polarization program. The
cytokine TGFB is known to suppress the tumour inhibitory role of Th1 [26]. Correspondingly, we observe that genes that are upregulated in
these pathways confer poor prognosis (DMFS) (significant associations shown in blue). Genes implicated in the Th1 and Th2 pathways were
generally anticorrelated, indicative of an unbalanced differentiation program. It follows from this model that simultaneous high Th1 (IL2, IL12,
IFNG) and low TGFB would confer better prognosis than either high Th1 or low TGFB alone, in agreement with our observations.
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Page 16 of 20We should point out that many of the prognostic asso-
ciations we report here would only be marginal under a
Bonferroni corrected threshold of (0.05/24 ~ 0.002). On
the other hand a Bonferroni threshold is very stringent
(probability of one false positive is 0.05) and is known to
lead to a high false negative rate. Given the small number
of prognostic tests being carried out (24 independent tests
in total) and the clear skew towards small P-values (Kol-
mogorov-Smirnov test P = 0.001) suggests that these prog-
nostic P-values do not derive from a uniform distribution,
an indication that most of the associations reported here
are unlikely to be false positives.
We also observed strong correlations of T-cell helper-
1 pathways (IL12, IFNG, IL2) with the genes overex-
pressed in the prognostic immune-response (IR) module
(C 1 Q A ,L Y 9 ,H L A - F ,T N F R S F 1 7 ) [15], a strong correla-
tion between TGFB and the gene underexpressed in the
IR-module (SPP1), as well as a strong anti-correlation
between (C 1 Q A ,L Y 9 ,H L A - F ,T N F R S F 1 7 )a n dI L 1 3 ,
which mediates T-cell helper-2 immune responses
(Additional file 13). Thus, it is likely that the IR-module
we identified previously [15] reflects the combined high
and low activation of Th1 and TGFB pathways. Thus,
given the observed synergy of these two pathways, it is
tentative to suggest further that simultaneous modula-
tion of Th1 and TGFB may be a better treatment strat-
egy than targeting just one pathway, and further
supports the rationale for combinational therapies tar-
geting multiple pathways.
More generally, and using likelihood ratio tests, we
observed that prognostic models based on module inter-
actions gave better prognostic stratifications of samples
than those based on single pathways, supporting the
value of such models. Thus, in addition to the (IL12,
TGFB) interaction, we observed that high EGFR and
low IL12 activity provided a better prognostic model in
ER- breast cancer, while simultaneous high MYC high
RAS activity defined a better prognostic model in ER+
breast cancer. However, in the (MYC, RAS) case we
observed that this interaction model was not better than
that based on E2F3 alone, which was the strongest pre-
dictor of prognosis in ER+ disease, reflecting the well-
established prognostic role of cell-proliferation genes
[42]. Biologically, this makes sense because E2F3 acts
downstream from both MYC and RAS, and therefore
high E2F3 activity may reflect activating mutations in
genes other than MYC and RAS.
Conclusions
In summary, this work has applied a novel strategy for
estimating pathway module activity levels in clinical
tumours. Using this method we have shown that acti-
vation patterns of oncogenic and immune response
pathway modules synergize to provide an improved
prognostic classification of ER- breast cancer, further
supporting the rationale for combinational therapies.
Additional material
Additional file 1: Model signatures. Model signatures used in
manuscript. We provide the official gene symbol and the expected
change in gene expression in response to pathway activation.
Additional file 2: Validation of merging algorithm. Hierarchical
clustering of merged ER+ and ER- data sets together with the
distribution of intrinsic subtypes (SSP) and the cohort of origin
(COHORT). For the top 20 principal components from a PCA analysis we
plot the -log10(p-values) of association of the components with the SSP
subtype (red) and cohort of origin (black). Green line marks the -log10
(0.05) threshold.
Additional file 3: Direct correlation activity estimation. Predicted
ERBB2 and EGFR pathway activities based on Pearson or Spearman
correlations of the signatures of ERBB2 and EGFR pathway activation from
Bild et al [1] in our breast cancer data sets Set1 and Set2 combined.
Pathway activation was estimated on a per-sample basis using all
available genes present on the array in question. Spearman or Pearson
correlations are shown across the intrinsic subtypes.
Additional file 4: Modularity of pathways. Barplots showing the
number (x-axis indexes the module) and sizes (y-axis) of the inferred
modules for selected pathways in ER- and ER+ breast cancer, illustrating
the modularity structure of pathways.
Additional file 5: Intra-pathway module correlations. A)& C) Pearson
correlations between module activation levels within molecular
pathways. Only pathways with at least two modules of size larger or
equal than 10 genes were selected. A) ER- breast cancer. C) ER+ breast
cancer. B)Heatmap of pathway activity levels of the four predicted
modules of the E2F3 pathway in ER- breast cancer. D)Heatmap of
pathway activity levels of the four predicted modules of the RAS
pathway in ER+ breast cancer. (Blue = high activation, yellow = low
activation).
Additional file 6: Inferred selected modules. Inferred selected
modules within molecular pathways and for ER+ and ER- breast cancer.
Each row gives the interaction and directionality of expression of each
gene.
Additional file 7: Heatmap of module genes. Heatmaps of gene
expression (red = high, green = low) of the genes in selected modules.
A) ER- breast cancer. B) ER+ breast cancer. SSP = simple sample
predictor intrinsic subtype (red = basal, skyblue = lumA, blue = lumB,
green = normal, pink = HER2). PATHW labels pathway, UP/DOWN labels
if gene is up (black) or down (white) regulated. Grey denotes genes that
are part of multiple pathways.
Additional file 8: Pathway activation and SSP subtypes. For the ER+
and ER- breast cancer training (Set1) and validation (Set2) sets, we
provide a table listing the sign and p-values of the Wilcoxon rank sum
test for each pairwise comparison of pathway activity levels between
intrinsic subtypes and for each molecular pathway.
Additional file 9: Clinical outcome in Set2. For ER+ and ER- breast
cancers in Set2 and for each pathway, we give the hazard ratio, 95%CI
and the log-rank test P-value from a stratified Cox-proportional hazards
regression model with cohorts as strata and with distant metastasis free
survival (DMFS) as clinical endpoint. Pathway activation levels were
divided into high/low activity levels according to values larger/lower
than the median. Number of samples is given by n.
Additional file 10: KM-curves for IL12 and TGFB in ER- subtypes.
Kaplan Meier DMFS curves for the four subtypes stratified according to
up/down activity of the IL12 and TGFB pathways. Hazard ratio refers to
the IL12up-TGFBdn subtype relative to the rest. 95% confidence intervals
and log-rank test P-values are given. A) ER- basal samples in Set1. B) ER-
HER2+ samples in Set1.
Additional file 11: KM curves for IL12 and EGFR0. A) & B) Kaplan
Meier DMFS curves for dichotomised pathway activity levels, for IL12 and
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Page 17 of 20EGFR in ER- breast cancer (Set1), respectively. C) Kaplan Meier DMFS
curves for the four subtypes stratified according to up/down activity of
the IL12 and EGFR pathways in Set1. Hazard ratio refers to the IL12dn-
EGFRup subtype relative to the rest. 95% confidence intervals and log-
rank test P-values are given. D) As C) but in Set2.
Additional file 12: Synergy outcome maps in Set 2. Validation of
module interaction prognostic models in Set2. A) For the pathway
modules that correlated with DMFS in the ER positive and negative
breast cancer training sets and the corresponding best Boolean
interaction regression model, we evaluate the association with prognosis
in the validation Set2. x-axis denotes the log-likelihood of the
corresponding model. (Black = log-likelihood of model for first pathway
in pair, Grey = log-likelihood of model for second pathway in pair, Red =
log-likelihood of the best Boolean interaction model as determined from
training Set1, pink dashed line highlights those Boolean models with
improved log-likelihoods). B) Heatmaps of likelihood ratio test (LRT) p-
values comparing nested prognostic models in Set2. Specifically LRT p-
value for pathway py on y-axis and pathway px on x-axis is obtained by
comparing Cox-regression models with the single pathway px plus non-
linear Boolean interaction B(px, py) as predictors against the model with
only px as predictor. C) As B), but LRT p-value for pathway py on y-axis
and pathway px on x-axis is obtained by comparing Cox-regression
models with the single pathway px plus non-linear Boolean interaction B
(px, py) as predictors against the model with only B(px, py) as predictor.
Color codes: red (P < 0.01), pink (P < 0.05), white (P > 0.05).
Additional file 13: Relation of pathway modules to IR-module.
Correlation heatmaps between activation levels of immune response
related pathways and expression levels of the prognostic immune-
response (IR) module of [15] in ER positive and ER negative breast cancer
(Red = high correlation, White = zero or insignificant correlation, Green =
high anti-correlation). Of the seven genes in the IR-module, five were
present in Set1.
Abbreviations
ER+: (ER positive breast cancer); ER-: (ER negative breast cancer); (HRAS): Ha-
Ras1 proto-oncoprotein; (E2F3): E2F transcription factor 3; (MYC): c-myc
proto-oncogene protein; (EGFR): epidermal growth factor receptor; (ERBB2):
c-erb B2/neu protein; (AKT): AKT1 kinase; (IFNG): interferon-gamma; (TGFB):
transforming growth factor beta-1; (IL-2,4,12,13): interleukin-2,4,12,13.
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